Prognosis
Superbugs Win Another Round as Big Pharma Leaves Antibiotics
- Novartis shuts down efforts; Glaxo reviewing some assets
- Public measures to spur research not working for drug giants
Photographer: Getty Images
This article is for subscribers only.
The fight against life-threatening infections suffered another blow when one of the world’s biggest drugmakers waved the white flag.
Novartis AG is the latest drug giant to end antibacterial and antiviral research, joining the likes of AstraZeneca Plc, Sanofi, Allergan Plc and Medicines Co. GlaxoSmithKline Plc has put some antibiotics assets under review.